JP2005521685A - （３ｒ，５ｒ）７−［３−フェニル−４−フェニルカルバモイル−２−（４−フルオロフェニル）−５−イソプロピル−ピロール−１−イル］−３，５−ジヒドロキシヘプタン酸のヘミ−カルシウム塩（アトロバスタチン）の非晶質形を製造する方法 - Google Patents

（３ｒ，５ｒ）７−［３−フェニル−４−フェニルカルバモイル−２−（４−フルオロフェニル）−５−イソプロピル−ピロール−１−イル］−３，５−ジヒドロキシヘプタン酸のヘミ−カルシウム塩（アトロバスタチン）の非晶質形を製造する方法 Download PDF

Info

Publication number
JP2005521685A
JP2005521685A JP2003567871A JP2003567871A JP2005521685A JP 2005521685 A JP2005521685 A JP 2005521685A JP 2003567871 A JP2003567871 A JP 2003567871A JP 2003567871 A JP2003567871 A JP 2003567871A JP 2005521685 A JP2005521685 A JP 2005521685A
Authority
JP
Japan
Prior art keywords
solution
phenylcarbamoyl
fluorophenyl
isopropyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003567871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521685A5 (https=
Inventor
ラードル，スタニスラフ
スタフ，ヤン
Original Assignee
ゼンティーバ，アー．エス．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンティーバ，アー．エス． filed Critical ゼンティーバ，アー．エス．
Publication of JP2005521685A publication Critical patent/JP2005521685A/ja
Publication of JP2005521685A5 publication Critical patent/JP2005521685A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003567871A 2002-02-01 2003-01-30 （３ｒ，５ｒ）７−［３−フェニル−４−フェニルカルバモイル−２−（４−フルオロフェニル）−５−イソプロピル−ピロール−１−イル］−３，５−ジヒドロキシヘプタン酸のヘミ−カルシウム塩（アトロバスタチン）の非晶質形を製造する方法 Pending JP2005521685A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20020413A CZ296967B6 (cs) 2002-02-01 2002-02-01 Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
PCT/CZ2003/000007 WO2003068739A1 (en) 2002-02-01 2003-01-30 Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7- 3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)

Publications (2)

Publication Number Publication Date
JP2005521685A true JP2005521685A (ja) 2005-07-21
JP2005521685A5 JP2005521685A5 (https=) 2006-02-09

Family

ID=27674298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003567871A Pending JP2005521685A (ja) 2002-02-01 2003-01-30 （３ｒ，５ｒ）７−［３−フェニル−４−フェニルカルバモイル−２−（４−フルオロフェニル）−５−イソプロピル−ピロール−１−イル］−３，５−ジヒドロキシヘプタン酸のヘミ−カルシウム塩（アトロバスタチン）の非晶質形を製造する方法

Country Status (15)

Country Link
US (1) US7208608B2 (https=)
EP (1) EP1470106B1 (https=)
JP (1) JP2005521685A (https=)
KR (1) KR20040081172A (https=)
AT (1) ATE480516T1 (https=)
AU (1) AU2003213986A1 (https=)
CZ (1) CZ296967B6 (https=)
DE (1) DE60334068D1 (https=)
EA (1) EA007432B1 (https=)
ES (1) ES2347324T3 (https=)
HU (1) HUP0402590A3 (https=)
PL (1) PL209756B1 (https=)
PT (1) PT1470106E (https=)
UA (1) UA76826C2 (https=)
WO (1) WO2003068739A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520740C (en) * 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
ATE545629T1 (de) * 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
US8044086B2 (en) * 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
CA2582087A1 (en) * 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
WO2006048893A2 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited A process for synthesis of large particle size statin compounds
CA2499047A1 (en) 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
WO2007020413A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
AU2006281237A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) * 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) * 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
CN108774164A (zh) * 2018-05-29 2018-11-09 宣城美诺华药业有限公司 一种阿托伐他汀钙合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509230A (ja) * 1995-07-17 1999-08-17 ワーナー−ランバート・コンパニー 結晶性の〔Ｒ−（Ｒ▲上＊▼，Ｒ▲上＊▼）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン）
WO2001042209A1 (en) * 1999-12-10 2001-06-14 Lek Pharmaceutical And Chemical Company D.D. Process for the preparation of amorphous atorvastatin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848704T1 (en) * 1995-07-17 2002-04-30 Warner-Lambert Company Form iii crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (https=) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
IN190564B (https=) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
WO2003018547A2 (en) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509230A (ja) * 1995-07-17 1999-08-17 ワーナー−ランバート・コンパニー 結晶性の〔Ｒ−（Ｒ▲上＊▼，Ｒ▲上＊▼）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン）
WO2001042209A1 (en) * 1999-12-10 2001-06-14 Lek Pharmaceutical And Chemical Company D.D. Process for the preparation of amorphous atorvastatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009038038, Ｋｅｌｖｉｎ Ｌ． Ｂａｕｍａｎｎ， ｅｔ ａｌ．, Ｔｅｔｒａｈｅｄｒｏｎ Ｌｅｔｔｅｒｓ, 1992, ３３（１７）, ２２８３−２２８４頁 *

Also Published As

Publication number Publication date
PL209756B1 (pl) 2011-10-31
EP1470106B1 (en) 2010-09-08
CZ296967B6 (cs) 2006-08-16
US7208608B2 (en) 2007-04-24
EP1470106A1 (en) 2004-10-27
PT1470106E (pt) 2010-09-23
US20050131055A1 (en) 2005-06-16
UA76826C2 (uk) 2006-09-15
DE60334068D1 (de) 2010-10-21
KR20040081172A (ko) 2004-09-20
ES2347324T3 (es) 2010-10-28
WO2003068739A1 (en) 2003-08-21
HUP0402590A2 (hu) 2005-03-29
HUP0402590A3 (en) 2010-06-28
EA200400977A1 (ru) 2004-12-30
PL370495A1 (en) 2005-05-30
EA007432B1 (ru) 2006-10-27
CZ2002413A3 (cs) 2003-10-15
ATE480516T1 (de) 2010-09-15
AU2003213986A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
JP2005521685A (ja) （３ｒ，５ｒ）７−［３−フェニル−４−フェニルカルバモイル−２−（４−フルオロフェニル）−５−イソプロピル−ピロール−１−イル］−３，５−ジヒドロキシヘプタン酸のヘミ−カルシウム塩（アトロバスタチン）の非晶質形を製造する方法
JP5416403B2 (ja) 純粋な非結晶ロスバスタチンカルシウムの調製方法
US7994343B2 (en) Process for the production of atorvastatin calcium in amorphous form
CZ2005427A3 (cs) Zpusob výroby hemivápenáté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
CN1307187C (zh) 瑞舒伐他汀及其中间体的制备方法
KR100905139B1 (ko) 4-페닐부티르산의 합성
CN113788766A (zh) 一种阿托伐他汀钙中间体的制备方法
EP1704144B1 (en) A method of preparation of the hemi-calcium salt of (e)-7- [4-(4-fluorophenyl)-6-isopropyl-2- [me thyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxy-6-heptenoic acid
US20080188664A1 (en) Process for preparing montelukast sodium containing controlled levels of impurities
JPH08506332A (ja) テトラゾール−５−カルボン酸誘導体の製法
US7112604B2 (en) Process for the preparation of Atorvastatin and intermediates
JP2008510798A (ja) 非晶質アトルバスタチンカルシウムのための方法
WO2008087628A1 (en) Process for preparing montelukast sodium containing controlled levels of impurities
CN112939900B (zh) 一种布瓦西坦中间体的制备方法
US7615647B2 (en) Process for producing atorvastatin hemicalcium
RU2707043C1 (ru) Способ получения гербицида имазамокса
RU2667903C1 (ru) Способ получения гидроксамида олеиновой кислоты
CN1492862A (zh) 从华法令酸制备华法令钠的方法
WO2005073187A1 (en) Improved process for the preparation of amorphous atorvastatin calcium
JP2008521804A (ja) ベンズフェタミンの結晶化方法
US20130143957A1 (en) Polymorphic forms of warfarin potassium and preparations thereof
WO2005033078A1 (en) Process for the production of atorvastatin calcium
JP2002069062A (ja) ３−ヒドロキシイソオキサゾールを製造する方法
JP2003040855A (ja) 含フッ素コハク酸系化合物の固液分離可能な晶析方法
JPS6148832B2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100518